AssetMark Inc
CYTK icon

AssetMark Inc’s Cytokinetics CYTK Stock Holding History

AssetMark Inc’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$408K Buy
4,795
+1,332
+38% +$95.6K ﹤0.01% 1279
2026
Q1 		$228K Buy
3,463
+438
+14% +$27.8K ﹤0.01% 1321
2025
Q4 		$192K Sell
3,025
-338
-10% -$21K ﹤0.01% 1318
2025
Q3 		$185K Buy
3,363
+721
+27% +$29.7K ﹤0.01% 1282
2025
Q2 		$87.3K Buy
2,642
+1,481
+128% +$51.5K ﹤0.01% 1399
2025
Q1 		$46.7K Buy
1,161
+1,151
+11,510% +$52.9K ﹤0.01% 1457
2024
Q4 		$470 Buy
+10
New +$519 ﹤0.01% 2383
2024
Q1 		– Sell
-4
Closed -$334 – 1974
2023
Q4 		$334 Buy
+4
New +$145 ﹤0.01% 1712
2018
Q1 		– Sell
-15
Closed – – 1543
2017
Q4 		$0 Buy
+15
New +$170 ﹤0.01% 1920
2017
Q1 		– Sell
-34
Closed – – 1295
2016
Q4 		$0 Buy
+34
New +$361 ﹤0.01% 1266

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AssetMark Inc's CYTK Position: Q2 2026 in Review

AssetMark Inc increased its Cytokinetics (CYTK) stake by 38% in Q2 2026, buying an estimated $95.6K and bringing the position to 4,795 shares worth $408K. The position accounts for ﹤0.01% of the portfolio, ranked #1279.

AssetMark Inc first reported a position in CYTK in Q4 2016 and has held it in 10 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • AssetMark Inc held 4,795 shares of Cytokinetics worth $408K as of Q2 2026.
  • AssetMark Inc bought 1,332 Cytokinetics shares in Q2 2026, an estimated $95.6K.
  • Cytokinetics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1279 holding.
  • AssetMark Inc first reported a position in Cytokinetics in Q4 2016 and has held it in 10 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.